Antibody Drug Conjugates Market Insights, Forecast to 2025


Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment.

The preparation process of ADCs involves great difficulty, inspite of these hurdles recently approved ADCs have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADCs that promises revolutionary changes in area of targeted therapy for cancer treatment. 

This market is driven by elements such as continuous improvement in the clinical data and technological advancements in the field of drug development shelling out innovative drugs into the market.

The global Antibody Drug Conjugates market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019–2025. The objectives of this study are to define, segment, and project the size of the Antibody Drug Conjugates market based on company, product type, end user and key regions.

Download FREE Sample of this Report @

This report studies the global market size of Antibody Drug Conjugates in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Antibody Drug Conjugates in these regions.

This research report categorizes the global Antibody Drug Conjugates market by top players/brands, region, type and end user. This report also studies the global Antibody Drug Conjugates market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

  • F. Hoffman-La Roche
  • Novartis AG
  • Takeda Pharmaceutical
  • Pfizer
  • Seattle Genetics
  • Genentech
  • Immunogen
  • Progenics Pharmaceuticals
  • Bayer Healthcare Pharmaceuticals

Market size by Product

  • Adcetris
  • Kadcyla
  • Market size by End User
  • Breast Cancer
  • Lymphoma

Market size by Region

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Singapore
  • Malaysia
  • Philippines
  • Thailand
  • Vietnam

The study objectives of this report are:

  • To study and analyze the global Antibody Drug Conjugates market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
  • To understand the structure of Antibody Drug Conjugates market by identifying its various subsegments.
  • To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
  • Focuses on the key global Antibody Drug Conjugates companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
  • To project the value and sales volume of Antibody Drug Conjugates submarkets, with respect to key regions.
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Antibody Drug Conjugates are as follows:

  • History Year: 2014–2018
  • Base Year: 2018
  • Estimated Year: 2019
  • Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Antibody Drug Conjugates market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get the Complete Report & TOC @

Table of content

1 Study Coverage
1.1 Antibody Drug Conjugates Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Antibody Drug Conjugates Market Size Growth Rate by Product
1.4.2 Adcetris
1.4.3 Kadcyla
1.5 Market by End User
1.5.1 Global Antibody Drug Conjugates Market Size Growth Rate by End User
1.5.2 Breast Cancer
1.5.3 Lymphoma
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Antibody Drug Conjugates Market Size
2.1.1 Global Antibody Drug Conjugates Revenue 2014–2025
2.1.2 Global Antibody Drug Conjugates Sales 2014–2025
2.2 Antibody Drug Conjugates Growth Rate by Regions
2.2.1 Global Antibody Drug Conjugates Sales by Regions
2.2.2 Global Antibody Drug Conjugates Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Antibody Drug Conjugates Sales by Manufacturers
3.1.1 Antibody Drug Conjugates Sales by Manufacturers
3.1.2 Antibody Drug Conjugates Sales Market Share by Manufacturers
3.1.3 Global Antibody Drug Conjugates Market Concentration Ratio (CR5 and HHI)
3.2 Antibody Drug Conjugates Revenue by Manufacturers
3.2.1 Antibody Drug Conjugates Revenue by Manufacturers (2014–2019)
3.2.2 Antibody Drug Conjugates Revenue Share by Manufacturers (2014–2019)

276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414

Follow Us On linkedin :-


Please enter your comment!
Please enter your name here